Heudobler, D., Luke, F., Hahn, J., Grube, M., Schlosser, P., Kremers, S., . . . Thomas, S. (2024). Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): Results of the safety run-in phase. Haematologica, 109(4), . https://doi.org/10.3324/haematol.2023.283864
Chicago-Zitierstil (17. Ausg.)Heudobler, Daniel, et al. "Low-dose Azacitidine, Pioglitazone and All-trans Retinoic Acid Is Safe in Patients Aged ≥60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase." Haematologica 109, no. 4 (2024). https://doi.org/10.3324/haematol.2023.283864.
MLA-Zitierstil (9. Ausg.)Heudobler, Daniel, et al. "Low-dose Azacitidine, Pioglitazone and All-trans Retinoic Acid Is Safe in Patients Aged ≥60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase." Haematologica, vol. 109, no. 4, 2024, https://doi.org/10.3324/haematol.2023.283864.